AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL

New drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy.

$AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL$

"Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and administered subcutaneously." Credit: Genmab A/S

Already have an account? Sign in.